Table 4: Changes in Different Parameters of the SF-36 Questionnaire Compared to the Placebo Phase. The Patients who Used the Specified Medication at the Visits Three (Week 12), Four (Week 18) and Five (Week 24). General Linear Method, Measurements at 0, 6, 12, 18 and 24 Weeks. Statistically Significant Changes are Bolded

Comparison	Physical Functioning	Role- Physical	Bodily Pain	General Health	Total Physical Health	Vitality	Social Functioning	Role- Emotional	Mental Health	Total Mental Health	General Health	Health Transition	Total SF-36
Candesartan 8/16 mg vs placebo (n=69, week 12)
change	-3.3	-1.4	-1	+0.42	+0.1	+2.3	+0.5	+1.4	+0.7	+1.0	-0.2	+0.1	-1.1
SD	14.0	24.2	18.0	15.0	8.5	14.6	11.2	27.1	12.2	9.9	0.8	0.6	14.6
p-value	0.083	0.435	0.157	0.347	0.254	0.213	0.414	0.298	0.708	0.173	0.014	0.398	0.789
Candesartan 8/16 mg ± HCTZ 12.5/25 mg vs placebo (n=65, week 18)
change	-1.1	-1.2	+1.5	+0.6	+0.4	+2.6	+0.4	+4.1	+0.7	+1.4	-0.3	-0.2	+1.8
SD	6.8	34.0	20.7	12.2	11.4	16.2	12.9	29.8	13.5	12.0	0.7	0.9	15.6
p-value	0.042	0.783	0.352	0.360	0.360	0.422	0.910	0.230	0.904	0.453	0.014	0.133	0.982
Candesartan 8/16 mg + HCTZ 12.5/25 mg ± felodipin 5 mg vs placebo (n=65, week 24)
change	-1.2	+2.3	+1.2	-1.1	+0.1	-1.0	+1.2	+3.1	+2.4	+0.8	-0.1	-0.1	+0.4
SD	23.3	41.6	30.0	24.7	19.2	23.9	20.8	42.0	15.1	19.0	1.1	1.1	25.5
p-value	0.736	0.982	0.720	0.739	0.959	0.523	0.985	0.703	0.647	0.930	0.093	0.178	0.330